8-K: Cara Therapeutics Stockholders Approve Merger with Tvardi Therapeutics

Cara Therapeutics stockholders greenlit the merger with Tvardi Therapeutics, paving the way for a reverse recapitalization.

Summary

• Cara Therapeutics, Inc. held a Special Meeting of Stockholders on April 1, 2025, where stockholders voted on six proposals related to the merger with Tvardi Therapeutics, Inc.
• All six proposals were approved, including the issuance of Cara's common stock pursuant to the merger with Tvardi, which will result in Tvardi becoming a wholly-owned subsidiary of Cara.
• The merger will represent more than 20% of Cara's outstanding common stock and result in a change of control.
• Stockholders also approved the Tvardi Therapeutics, Inc. 2025 Equity Incentive Plan and the Tvardi Therapeutics, Inc. 2025 Employee Stock Purchase Plan.
• An amendment to Cara's certificate of incorporation was approved to effect a reverse stock split at a ratio in the range of 1-for-2 to 1-for-4.
• Stockholders approved an increase in the number of authorized shares of Cara's common stock from 16,666,667 to 150,000,000 shares.
• The audited financial statements of Tvardi as of and for the years ended December 31, 2024 and 2023, along with management's discussion and analysis, and unaudited pro forma condensed combined financial statements as of and for the year ended December 31, 2024, relating to the proposed Merger are included in the report.
• As of February 5, 2025, the record date for the Special Meeting, there were 4,571,229 shares of Cara's common stock issued and outstanding.
• A total of 2,257,479 shares were represented at the meeting, constituting approximately 49.38% of the outstanding common stock.

Sentiment

Score: 7

Explanation: The document is generally positive due to the successful stockholder vote and progress towards the merger. However, the risks and uncertainties associated with the merger and future operations temper the overall sentiment.

Positives

• Stockholder approval of all merger-related proposals indicates strong support for the transaction.
• The increase in authorized shares provides flexibility for future capital raising and corporate actions.
• The merger with Tvardi is expected to create a combined company with a stronger pipeline and financial position.

Risks

• The pro forma financial statements are based on assumptions and estimates and do not guarantee future performance.
• The unaudited pro forma condensed combined financial statements have been prepared on the basis of certain assumptions and estimates and are subject to other uncertainties and do not purport to reflect what the actual results of operations or financial condition of the combined company would have been had the Merger been consummated on the dates assumed for purposes of such pro forma financial statements or to be indicative of the financial condition or results of operations of the combined company as of or for any future date or period.
• Forward-looking statements are subject to risks and uncertainties, and actual results may differ materially.
• The completion of the Merger is subject to customary closing conditions and there is no guarantee that the merger will be completed.

Future Outlook

Tvardi expects its expenses and capital requirements to increase substantially in the foreseeable future, particularly as it advances its product candidates through clinical development and seeks regulatory approvals.

Industry Context

The merger reflects a trend of consolidation in the biopharmaceutical industry, where companies seek to combine resources and pipelines to enhance their competitive position.

Stakeholder Impact

• Shareholders of Cara Therapeutics will see their ownership diluted upon completion of the merger.
• Employees of both Cara Therapeutics and Tvardi Therapeutics may experience changes in their roles and responsibilities.
• The combined company will continue to develop and commercialize therapies for fibrosis-driven diseases, potentially benefiting patients with unmet medical needs.

Next Steps

• Completion of the merger between Cara Therapeutics and Tvardi Therapeutics.
• Nasdaq approval of the listing of shares of Cara common stock to be issued in connection with the Merger.
• Continued development of Tvardi's product candidates, including TTI-101 and TTI-109.
• Potential future capital raising activities to fund operations and clinical trials.

Key Dates

Keywords

Merger, Tvardi Therapeutics, Cara Therapeutics, Stockholders, Reverse Stock Split, Common Stock, Equity Incentive Plan, Employee Stock Purchase Plan, Authorized Shares, Financial Statements